Kintor Pharmaceutical Limited announced that (i) with effect from 10 May 2021, Dr. Qun Lu ("Dr. Lu") has been appointed as chief technology officer, who will be primarily responsible for Chemistry, Manufacturing, and Control (the "CMC") including drug analysis, formulation development and the production; and (ii) with effect from 15 May 2021, Dr. Jiawen Han ("Dr. Han") has been appointed as vice president of business development, who will be primarily responsible for business development-related projects and management. Dr. Lu has over 20 years of experience in biopharmaceutical industry with proven track record of successfully leading the CMC development of pharmaceutical dosage forms from discovery through commercialisation at various pharmaceutical corporations including Pfizer, Merck and Celgene Corp./Bristol Myers Squibb (the "BMS").